CoChat

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

Open access

The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists are a class of newly introduced antidiabetic medications that potentially lower blood glucose by several molecular pathways. DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release. Most patients with diabetes have concurrent hypertension and cardiovascular disorder. If antihyperglycemic agents can attenuate the risk of hypertension and cardiovascular disease, they will amplify their overall beneficial effects. There is conflicting evidence on the cardiovascular benefits of GLP-1R induction in laboratory studies and clinical trials. In this study, we have reviewed the main molecular mechanisms by which GLP-1R induction may modulate the cardiovascular function and the results of cardiovascular outcome clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2021/6518221

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The mechanism by which GLP-1RA and DPP-4i act on various organs.
Figure 1 The mechanism by which GLP-1RA and DPP-4i act on various organs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 118 references

Research works printed but not linked: 2

  1. 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
  2. S. Hosokawa, 2014, The synergistic effects of incretin-related drugs for the treatment of pulmonary arterial hypertension, American Heart Association, 130, article A13535

Cited by

See all 31

Metadata

Authors
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A.
Affiliations
  • Semnan University of Medical Sciences (IR)
  • Shahid Beheshti University (IR)
  • University of Hull (GB)
  • Medical University of Lodz (PL)
  • Mashhad University of Medical Sciences (IR)
Corresponding author
  • Yaribeygi, Habib
  • Sahebkar, Amirhossein
Venue
Journal of Diabetes Research
Publisher
Wiley
Published
2021-06-30
Volume
2021
Pages
1-10
ISSN
  • 2314-6745 (ISSN-L)
  • 2314-6753
OpenAlex
W3175947914
Cited by
31
References
118
Citations by year
2026: 5 · 2025: 11 · 2024: 4 · 2023: 8 · 2022: 2 · 2021: 1
FWCI
0.58
Type
journal article
Language
en
Open access
Locations
  • Journal of Diabetes Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Baqiyatallah Hospital
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, DPP-4 inhibitors, blood pressure, hypertension, cardiovascular complications, diabetes mellitus, antidiabetic drugs, cardiovascular outcome trials, glucagon-like peptide-1, insulin secretion, glucagon suppression, antihypertensive effect
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Autonomic Nervous System, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endothelium, Vascular, Heart Rate, Humans, Hypertension, Hypoglycemic Agents, Nitric Oxide, Renin-Angiotensin System, Comorbidity, Treatment Outcome, Oxidative Stress, Diabetes Complications, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes. https://app.cochat.ai/papers/10.1155/2021/6518221
The paper
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021). The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes. Journal of Diabetes Research. https://doi.org/10.1155/2021/6518221

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.